Biology problem
Late detection by existing imaging techniques.
ctDNA can be detected 9–12 months earlier and creates a window for therapeutic intervention.
Enabling MRD ecosystem with
Accessible, scalable ultrasensitive cancer monitoring technology
2Strands is an early-stage precision diagnostic company developing an allele specific enrichment technology for detection of rare variants in circulating tumour DNA.
Ultra-sensitive
Detection
ctDNA
Blood-based
MRD
Monitoring
Backed & supported by
The problem
Recurrence is detectable long before it is detected.
Accessibility problem
ctDNA detection requires ultradeep and broad sequencing.
Not accessible to all labs across different health systems.
Our solution
Enrich the signal first, so depth stops being the price of sensitivity.
Enrich mutant signals
2Strands enriches ctDNA signals before sequencing, enabling ultrasensitive detection of cancer recurrence (MRD) at significantly lower sequencing depth.
Expand access and scalability
By reducing reliance on ultra-deep sequencing, our technology makes post-treatment recurrence detection and serial monitoring more accessible and scalable.
The technology
2Strands allele enrichment platform
Our platform selectively enriches target mutations while depleting non-target alleles.
This reduces sequencing requirements, enables detection of multiple low-frequency mutations, and helps lower cost while delivering best-in-class sensitivity and specificity to make MRD accessible and scalable.
Value proposition
Accessible and scalable ultrasensitive MRD technology
Access
Expand access
Bring ultrasensitive MRD detection beyond a limited number of elite health systems.
Enable serial monitoring
Make repeated testing after curative treatment more economically viable.
Operational efficiency
Protect margins
Strengthen test economics amid reimbursement pressure.
Increase throughput
Process more samples with fewer sequencing reads required per test.
Newsroom
See all →
News & Updates
8 July 2026
2Strands Named One of LSI Asia 2026’s “Five Innovators to Watch”
3 February 20262Strands Secures Pre-Seed Funding to Accelerate Technology Development
October 20252Strands Strengthens Its Intellectual Property Portfolio with Two Patent Milestones
30 May 20252Strands Selected for MedTech Innovator’s 2025 Asia Pacific Accelerator
Behind the science
Our Team
The 2Strands Biosciences team brings together extensive expertise in Molecular Biology, Genomics and Diagnostic commercialisation.
Careers
Join Us
We are always on a lookout for driven and outstanding candidates with experience in assay development, NGS bioinformatics, and diagnostic development and commercialisation. For enquires about a role or internship opportunities, kindly fill up the contact form below.
Get in touch →
Get in touch
Contact us
If you'd like to get in touch with us, please fill up the contact form below.
2Strands Biosciences Pte Ltd21 Biopolis Road, #05-01, Nucleos, Singapore 138567
Email usadmin@2Strandsbiosciences.com
Connect with usLinkedIn → 2Strands Biosciences